| 2 | 1/1 | 返回列表 |
| 查看: 305 | 回復(fù): 1 | |||
zlwcw木蟲(chóng) (著名寫(xiě)手)
|
[交流]
WuXi PharmaTech Acquires China-Based Clinical Research Services Companies 已有1人參與
|
|
WuXi PharmaTech Acquires China-Based Clinical Research Services Companies SHANGHAI, October 24, 2011 /PRNewswire via COMTEX/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development services company with operations in China and the United States, today announced the acquisition of MedKey Med-Tech Development Co. Ltd. and Jiecheng Med-Tech Development Co. Ltd., two related contract clinical research services companies based in Shanghai, China. The financial terms of the transaction were not disclosed. Founded in 2006, MedKey/Jiecheng have about 80 employees and operate in 15 cities in China, with offices in Shanghai, Beijing, and Guangzhou. The companies provide services in regulatory affairs, Phase I-IV clinical trial management, and clinical trial site management throughout most of the regions in China. Their customer base includes both multinational pharmaceutical companies and domestic Chinese pharmaceutical companies. David Xi, founder, owner, and CEO of the companies, will continue to manage MedKey/Jiecheng as WuXi’s Executive Director of Clinical Operations. As part of WuXi, MedKey/Jiecheng will leverage WuXi’s broad customer base and will focus on clinical services needed by customers for Chinese regulatory filings and market access. “WuXi’s acquisition of Medkey/Jiecheng continues our strategy to build an integrated platform of R&D services that will allow anyone and any company to discover and develop drugs more efficiently and cost effectively for patients,” said Dr. Ge Li, Chairman and CEO of WuXi. “This acquisition provides WuXi an existing clinical development service capability and infrastructure that WuXi will expand and strengthen to serve our customers’ growing clinical development needs in the fast-growing Chinese healthcare market.” |
木蟲(chóng) (著名寫(xiě)手)

| 2 | 1/1 | 返回列表 |
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 279求調(diào)劑 +4 | 紅衣隱官 2026-03-21 | 4/200 |
|
|---|---|---|---|---|
|
[考研] 求調(diào)劑 +3 | 白QF 2026-03-21 | 3/150 |
|
|
[考研] 330求調(diào)劑0854 +3 | assdll 2026-03-21 | 3/150 |
|
|
[考研] 299求調(diào)劑 +4 | shxchem 2026-03-20 | 6/300 |
|
|
[考研] 材料學(xué)學(xué)碩080502 337求調(diào)劑-一志愿華中科技大學(xué) +4 | 順順順mr 2026-03-18 | 5/250 |
|
|
[考研] 330求調(diào)劑 +4 | 小材化本科 2026-03-18 | 4/200 |
|
|
[考研] 求調(diào)劑,一志愿:南京航空航天大學(xué)大學(xué) ,080500材料科學(xué)與工程學(xué)碩,總分289分 +4 | @taotao 2026-03-19 | 4/200 |
|
|
[考研] 一志愿蘇州大學(xué)材料求調(diào)劑,總分315(英一) +5 | sbdksD 2026-03-19 | 5/250 |
|
|
[考研] A區(qū)線材料學(xué)調(diào)劑 +5 | 周周無(wú)極 2026-03-20 | 5/250 |
|
|
[考研] 環(huán)境工程調(diào)劑 +9 | 大可digkids 2026-03-16 | 9/450 |
|
|
[考研] 0703化學(xué)調(diào)劑 +10 | 妮妮ninicgb 2026-03-15 | 14/700 |
|
|
[考研] 286求調(diào)劑 +6 | lemonzzn 2026-03-16 | 10/500 |
|
|
[考研] 0703化學(xué)調(diào)劑 +5 | pupcoco 2026-03-17 | 8/400 |
|
|
[考研] 材料工程專碩調(diào)劑 +5 | 204818@lcx 2026-03-17 | 6/300 |
|
|
[考研] 收復(fù)試調(diào)劑生 +4 | 雨后秋荷 2026-03-18 | 4/200 |
|
|
[考研] 考研化學(xué)學(xué)碩調(diào)劑,一志愿985 +4 | 張vvvv 2026-03-15 | 6/300 |
|
|
[考研] 290求調(diào)劑 +3 | p asserby. 2026-03-15 | 4/200 |
|
|
[考研] 一志愿蘇州大學(xué)材料工程(085601)專碩有科研經(jīng)歷三項(xiàng)國(guó)獎(jiǎng)兩個(gè)實(shí)用型專利一項(xiàng)省級(jí)立項(xiàng) +6 | 大火山小火山 2026-03-16 | 8/400 |
|
|
[考研] 326求調(diào)劑 +4 | 諾貝爾化學(xué)獎(jiǎng)覬?/a> 2026-03-15 | 7/350 |
|
|
[考研] 326求調(diào)劑 +3 | mlpqaz03 2026-03-15 | 3/150 |
|